BERGENBIO PRESENTS UPDATED CLINICAL DATA FROM TWO PHASE II STUDIES OF BEMCENTINIB IN AML AND MDS PATIENTS AT ASH 2020
· Clinical benefit rate of 73% reported in second line relapsed AML patients. Overall Response OOR 45%, CR/CRi rate of 36% · Median treatment duration exceeding 6 months with some patients remaining on study Bergen, Norway, 6 DECEMBER 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will present updated clinical data from two Phase II studies of bemcentinib in acute myeloid leukemia and high-risk myelodysplastic syndrome, in two poster sessions at the American Society of